Michael A. Blazing - Concepedia

Author

Michael A. Blazing

Also Known As

Kenneth W. Mahaffey, M BLAZING, M Blazing, M. A. Blazing, M. Blazing, M.A Blazing, M.A. Blazing, Michael A BLAZING, Michael A Blazing, Michael A. Blazing

174

Publications

15.5K

Citations

H-Index

107

Concepts

All Affiliations

Clinical Research Institute Duke University Brigham and Women's Hospital Duke Medical Center Thrombolysis in Myocardial Infarction Study Group

About

Michael A. Blazing is an author at Clinical Research Institute specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	31	4.1K
2	Public Health	11	11	2.8K
3	Health Sciences	8	8	393
4	Engineering	1	1	15
5	Natural Sciences	1	1	188

Michael A. Blazing

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes Christopher P. Cannon, Michael A. Blazing, Robert P. Giugliano, New England Journal of Medicine	2015	4.3K
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes James A. de Lemos, Michael A. Blazing, Stephen D. Wiviott, JAMA Percutaneous Coronary InterventionThrombosisAcs EventCardiovascular DiseaseEarlier Initiation	2004	1.3K
Relationship of Depression to Increased Risk of Mortality and Rehospitalization in Patients With Congestive Heart Failure Wei Jiang, Jude D. Alexander, Eric J. Christopher, Archives of Internal Medicine	2001	934
The incidence and functional consequences of RT-associated cardiac perfusion defects Lawrence B. Marks, Xiaoli Yu, Robert G. Prosnitz, International Journal of Radiation OncologyBiologyPhysics Heart FailureCardiovascular DiseaseMyocardial InfarctionFunctional ConsequencesCardiac Pathology	2005	440
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Robert P. Giugliano, Christopher P. Cannon, Michael A. Blazing, Circulation	2017	414
Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT Erin A. Bohula, Robert P. Giugliano, Christopher P. Cannon, Circulation	2015	327
Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial David A. Morrow, James A. de Lemos, Marc S. Sabatine, Circulation	2006	311
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Christopher P. Cannon, Robert P. Giugliano, Michael A. Blazing, American Heart Journal ThrombosisCardiovascular DiseaseCardiovascular OutcomesImproved ReductionClinical Trials	2008	297
Prognostic Value of Anxiety and Depression in Patients With Chronic Heart Failure Wei Jiang, Maragatha Kuchibhatla, Michael S. Cuffe, Circulation	2004	266
Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and Aspirin<SUBTITLE>A Randomized Controlled Trial</SUBTITLE> Michael A. Blazing JAMA	2004	253

Page 1